Piper Sandler analyst Alexander Goldfarb maintains Innovative Ind Props (NYSE:IIPR) with a Overweight and lowers the price target from $135 to $117.
IDEAYA Announces Achievement Of First Milestone In Ongoing Collaboration With GSK For Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
Preclinical development milestone achieved in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC as combo with niraparib
Potential to realize preclinical and clinical